Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00689078 · ClinicalTrials.gov registry record · Phase 4
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
A Phase 4 study of Allergic Conjunctivitis, sponsored by ORA.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00689078 is a Phase 4 study of Allergic Conjunctivitis that has completed, run by ORA. The registered enrollment target is 36 participants, below the 133-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00689078, a Phase 4 study of Allergic Conjunctivitis, has completed, sponsored by ORA.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the efficacy of prednisolone acetate 1% ophthalmic suspension as compared to prednisolone acetate 0.12% ophthalmic suspension, loteprednol etabonate 0.2% ophthalmic suspension, and placebo (Tears Naturale® II) in the prevention of the signs and symptoms of allergic conjunctivitis. Comparisons will be made following 1 week of twice daily (BID) dosing and 1 week of four times daily (QID) dosing.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Prednisolone Acetate 1%
- DRUG Prednisolone Acetate 0.12%
- DRUG Loteprednol Etabonate 0.2%
Study Locations (1)
Massachusetts
- Ophthalmic Research Associates - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2008-05 |
| Est. Completion | 2008-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00689078
The ClinicalTrials.gov registry entry for NCT00689078 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 133-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (73% lower). The listed sponsor is ORA, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00689078 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00689078 about?
NCT00689078 is a clinical study titled "Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model". To evaluate the efficacy of prednisolone acetate 1% ophthalmic suspension as compared to prednisolone acetate 0.12% ophthalmic suspension, loteprednol etabonate 0.2% ophthalmic suspension, and placebo (Tears Naturale® II) in the prevention of the signs and symptoms of allergic conjunctivitis. Compar...
What is the current status of trial NCT00689078?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2008-05. Estimated completion is 2008-06.
What conditions does trial NCT00689078 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT00689078?
The interventions under investigation include: Placebo (DRUG), Prednisolone Acetate 1% (DRUG), Prednisolone Acetate 0.12% (DRUG), Loteprednol Etabonate 0.2% (DRUG).
Who is sponsoring clinical trial NCT00689078?
This trial is sponsored by ORA, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00689078 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Alcon's Ocular Image Quantification System
COMPLETED · Phase 4
-
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis
COMPLETED · Phase 4
-
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
COMPLETED · Phase 4
-
Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis
COMPLETED · Phase 4
-
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
RECRUITING · Phase 2
-
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.